This is what I mean when I say the "science is solid". Aphios provides bryostatin for many studies, in particular Louisiana State University where they license the drug much as Stanford does for us. They have a patent for an oil based bryostatin that you can take orally. They have conducted lots of pre-clinical studies confirming bryostatin for memory loss issues but all is pre-clinical and independent confirmation of synaptogenesis and Dr. Alkon's decades of research...although they do cite some of Dr. Alkon's research on their website. Aphios is conducting a phase 1/2a study for HIV currently.
I have not examined Aphios' patent(s) for an analog compound of Byrostatin (it is not for Bryostatin-1).
My point was, in my post on Seeking Alpha (dkitt), that Aphios is still years behind NTRP in the regulatory process of getting a FDA approved drug to market and as Whatsupp just explained "in a recent talk by Dr Alkon, he said that NTRP patent covers any PK epsilon enhancing drug. I.e. Any company that sells such a drug has to go through them."
News 
Market Data 
Discover 
AI
